CVS Health (CVS) Stock Rating Reaffirmed by Raymond James Financial

CVS Health (NYSE:CVS)‘s stock had its “buy” rating reiterated by analysts at Raymond James Financial in a research report issued to clients and investors on Monday.

Several other equities research analysts also recently weighed in on the company. Deutsche Bank reissued a “hold” rating on shares of CVS Health in a report on Tuesday. Royal Bank Of Canada set a $95.00 price objective on CVS Health and gave the company a “buy” rating in a report on Monday. Robert W. Baird set a $77.00 price objective on CVS Health and gave the company a “hold” rating in a report on Monday. Jefferies Group set a $76.00 price objective on CVS Health and gave the company a “hold” rating in a report on Monday. Finally, Loop Capital set a $73.00 price objective on CVS Health and gave the company a “hold” rating in a report on Monday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the company. CVS Health presently has a consensus rating of “Buy” and an average price target of $86.35.

CVS Health (NYSE:CVS) opened at $71.01 on Monday. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $76,095.96, a P/E ratio of 13.16, a P/E/G ratio of 1.29 and a beta of 0.89. CVS Health has a fifty-two week low of $66.45 and a fifty-two week high of $84.72.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.49 by $0.01. The firm had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.64 earnings per share. equities analysts anticipate that CVS Health will post 5.9 EPS for the current fiscal year.

In other news, EVP Thomas M. Moriarty sold 90,267 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the completion of the sale, the executive vice president now owns 70,102 shares in the company, valued at $5,580,820.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David M. Denton sold 237,078 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.65, for a total value of $18,883,262.70. Following the sale, the chief financial officer now owns 141,096 shares of the company’s stock, valued at approximately $11,238,296.40. The disclosure for this sale can be found here. Insiders have sold 714,125 shares of company stock valued at $58,119,381 in the last 90 days. Company insiders own 0.61% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Pathstone Family Office LLC raised its position in CVS Health by 341.0% in the second quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock worth $2,353,000 after acquiring an additional 982 shares in the last quarter. Wealthcare Advisory Partners LLC raised its position in CVS Health by 330.3% in the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 991 shares in the last quarter. Fieldpoint Private Securities LLC grew its holdings in CVS Health by 333.3% in the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after purchasing an additional 1,000 shares during the last quarter. Arcadia Investment Management Corp MI grew its holdings in CVS Health by 119.6% in the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after purchasing an additional 726 shares during the last quarter. Finally, TB Alternative Assets Ltd. acquired a new stake in CVS Health in the second quarter valued at $121,000. Hedge funds and other institutional investors own 82.24% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “CVS Health (CVS) Stock Rating Reaffirmed by Raymond James Financial” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/12/06/cvs-health-cvs-stock-rating-reaffirmed-by-raymond-james-financial.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

What are top analysts saying about CVS Health Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CVS Health Corp and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit